Independent laboratory testing of products containing ranitidine, including Zantac®, has found dangerous levels of N-nitrososdimethylamine (NDMA), a probable human carcinogen, in them. In fact, it has been uncovered that the amount of NDMA found in Zantac® is 3,171 times greater than the daily intake limit as stated by the FDA.
A History of Alerts and Recalls
From the time that the independent lab testing showed the dangerous amount of NDMA in Zantac® and other products, until now, updates have continued to pour in and ranitidine products have continued to be recalled.
- September 2019
- FDA issues a statement alerting the public that NDMA was found in samples of ranitidine.
- FDA announces voluntary recall of Sandoz ranitidine capsules following the detection of an impurity.
- FDA issues alert to health care professionals and patients to the voluntary recall of ranitidine medications manufactured by Apotex Corp and labeled by Walgreens, Walmart, and Rite-Aid.
- October 2019
- FDA urges manufacturers to conduct independent lab testing of ranitidine products for potential contamination, recommending the use of an LC-HRMS testing protocol.
- FDA announces voluntary recalls of ranitidine by manufacturers of the following: Perrigo Company plc, Sanofi, Dr. Reddy’s, Lannett Company Inc., and Novitium Pharma.
- November 2019
- FDA releases laboratory-testing results for NDMA in ranitidine and released a statement from the director of the FDA’s Center for Drug Evaluation and Research.
- FDA alerts public of additional voluntary recalls of ranitidine products by the manufacturers Aurobindo Pharma USA and Amneal Pharmaceuticals LLC.
- December 2019
- FDA requires additional testing of nizatidine and ranitidine as part of the agency’s ongoing effort to help ensure product safety.
- FDA alerts the public of Glenmark’s voluntary recall of ranitidine.
- January 2020
- FDA alerts the public of Mylan’s voluntary recall of nizatidine as well as Appco Pharma LLC’s recall of ani.
Cancers Linked to Zantac® (Ranitidine) Use
According to studies, the most common types of cancer that can result from ingesting Zantac® (ranitidine) include:
- Kidney Cancer
- Liver Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Bladder Cancer
- Stomach Cancer
- Intestinal Cancer
- Testicular Cancer
- Esophageal Cancer
- Colorectal Cancer
- Uterine Cancer
The Attorneys at Carter Mario Law Firm Can Help
If you or a loved one has taken Zantac® and subsequently suffered adverse effects from the drug, you may be entitled to compensation.